PRKCI

Across TCGA pan-cancer cohorts, PRKCI mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PRKCI data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRKCI mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRKCI expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

OV and CCRCC are the cancer types where PRKCI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.942	0.569	.006	12	view →
CCRCC	DFS	Quartile	III,IV	0.768	1.000	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PRKCI–OV (DFS)

Open the OV breakdown →